Long term inhibition of hip joint damage under tumor necrosis factor-alpha inhibitors in spondyloarthritis

Mahmoud, I.; Maatallah, Kaouther; Nessib, Dorra Ben; Belghali, S.; Abdelghani, Kawther Ben; Métoui, L.; Saidane, O.; Hamdi, Wafa; Zouari, B.; Salem, Kamel Ben; Tekaya, R.; Abdelmoula, L.

doi:10.1016/j.intimp.2020.106927

Cited by 7 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, the number of children with structural progression was very low under TNF‐inhibitor treatment. This result is by those reported in adults with hip arthritis (Mahmoud et al., 2020; Sulpice et al., 2009). Tocilizumab has been found to prevent peripheral structural lesions in patients with systemic JIA (Inaba et al., 2013).…”

Section: Discussionsupporting

confidence: 88%

Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohort

Hamdi

Ferjani

Carlomagno

et al. 2023

Musculoskeletal Care

Self Cite

View full text Add to dashboard Cite

ObjectivesHip involvement remains a predictor of severe juvenile idiopathic arthritis (JIA) course and carries a high risk of disability. This study aims to determine the factors of poor prognosis of hip involvement in patients with JIA and to assess the treatment response.MethodsThis is a multicenter observational cohort study. Patients were selected from the JIR Cohort database. Hip involvement was defined as clinically suspected and confirmed by an imaging tool. Follow‐up data were collected during 5 years.ResultsAmong the 2223 patients with JIA, 341(15%) patients had hip arthritis. Male gender, enthesitis‐related arthritis, and North African origin were factors associated with hip arthritis. Hip inflammation was associated with disease activity parameters during the first year, particularly Physician Global Assessment, joint count, and inflammatory marks. Structural hip progression was associated with early onset of the disease, a longer time to diagnosis, geographic origin, and JIA subtypes. Anti‐TNF therapy was found to be the only treatment able to effectively reduce structural damage progression.ConclusionThe early onset diagnostic delay, origin, and systemic subtype of JIA predict a poor prognosis of hip arthritis in children with JIA. The use of anti‐TNF was associated with a better structural prognosis.

show abstract

Section: Discussionsupporting

confidence: 88%

Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohort

Hamdi

Ferjani

Carlomagno

et al. 2023

Musculoskeletal Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among therapeutic studies of SpA patients with hip involvement, the BASRI-h method is often adopted to assess radiological changes of hip lesions ( 24 ). However, most hip involvement in AS is related to early coxitis and is characterized by inflammation of the subchondral BME and synovitis ( 7 , 26 ).…”

Section: Discussionmentioning

confidence: 99%

“…Hip involvement is difficult to cure, and it is considered an important cause of disability and poor prognosis in SpA, especially in ankylosing spondylitis (AS) (17,22). There has been greater attention recently regarding hip arthritis in SpA, and various clinical studies on TNF-a inhibitor treatment and classical disease-modifying anti-rheumatic drug (DMARD) treatment have been conducted to assess the clinical and/or radiographic progress of hip joint and function (23)(24)(25). TNFa inhibitor treatment has been demonstrated to be effective in patients with SpA and hip involvement.…”

Section: Discussionmentioning

confidence: 99%

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

et al. 2021

View full text Add to dashboard Cite

ObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.MethodsA total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-α inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).ResultsThe clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-α inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-α inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 ± 10.37 vs. 20.59 ± 9.41, p < 0.001); the control group only had slight improvement (p < 0.05).ConclusionsTNF-α inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-α in SpA patients with hip involvement to help guide targeted treatment.

show abstract

“…In known therapeutic studies of SpA patients with hip involvement, BASRI-h method was often adopted to study radiological changes of hip lesions [24]. However, most of the hip involvement in AS belongs to early coxitis characterized by in ammation of the subchondral bone marrow edema and synovitis [7,26], while BASRI-h method were performed based on structural damages which may not sensitively re ect the treatment effect to those patients in early and acute in ammation stages in short-time follow-up.…”

Section: Discussionmentioning

confidence: 99%

“…More attentions turned to focus on the hip arthritis in SpA, and varies clinical studies including TNF-α inhibitor treatment or classical DMARDs treatment were conducted to observe the clinical and/or radiographic progress of hip joint and function. [23][24][25]. TNF-α inhibitor treatment had been demonstrated to be effect for SpA patients with hip involvement.…”

Section: Discussionmentioning

confidence: 99%

The clinical and MRI effect of TNF-α inhibitor in spondyloarthritis patients with hip involvement: a real-world prospective clinical study

Zhang

Zheng

Han

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Hip involvement is an important cause of disability and poor prognostic in patients with spondyloarthritis (SpA). TNF-α inhibitor treatment had been demonstrated to be effective in SpA patients with hip arthritis, however, quantitative assessment with magnetic resonance imaging (MRI) in the long-term follow-up still needs further application.Methods: A total of 239 patients were involved in this study, MTX and SSZ were given as basic treatment. 165 patients received TNF-α inhibitor plus basic treatment and 74 patients received basic treatment only as control. The clinical symptoms were assessed at baseline, week 12, week 24, and week 52. The MRI performances of hip arthritis including bone marrow edema (BME) and synovitis were quantitatively assessed using Hip MRI Inflammation Scoring System (HIMRISS).Results: The clinical symptoms of ESR, CRP, BASDAI, Harris, and ASDAS-ESR of both groups got significant clinical remission at week 52 (p<0.001). However, the disease activity change levels at week 52 in control group were significantly worse than TNF group. In week 52, MRI performance showed significant remission trend in TNF-α inhibitor group versus baseline of which total HIMRISS scores decreased significantly ( 26.49±10.37 vs 20.59±9.41, p<0.001), but the control group only had slight improvement trend (p<0.05).Conclusions: TNF-α inhibitor could significantly and better improve the clinical and MRI manifestation of hip involvement in SpA patients than controls. Quantitative MRI assessment combined with clinical assessment could accurately evaluate the treatment effect of TNF-α for SpA patients with hip involvement, and help to guide targeted treatment.Trial registration: Chinese Clinical Trial Registry, ChiCTR-ONRC-11001846, Registered 28 November 2011. Retrospectively registered http://www.chictr.org.cn/showproj.aspx?proj=7701

show abstract

Long term inhibition of hip joint damage under tumor necrosis factor-alpha inhibitors in spondyloarthritis

Cited by 7 publications

References 19 publications

Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohort

Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohort

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

The clinical and MRI effect of TNF-α inhibitor in spondyloarthritis patients with hip involvement: a real-world prospective clinical study

Contact Info

Product

Resources

About